FDA Clears Novartis Drug Cosentyx As Steroid Alternative for Inflammatory Pain Causing Stiff Shoulders

The FDA approved Novartis AG's Cosentyx 150 mg to treat adults with polymyalgia rheumatica (PMR) who do not respond to or cannot tolerate corticosteroids. The approval is based on the Phase 3 REPLENISH study, which showed sustained remission rates of 40.5% for Cosentyx 150 mg compared to 20.5% for placebo. Novartis shares were down 1.07% premarket on Tuesday.

Original reporting
Published Nov 17, 2026, 2:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 3:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
FDA Clears Novartis Drug Cosentyx As Steroid Alternative for Inflammatory Pain Causing Stiff Shoulders — source image
Decision brief

The 30-second read

$NVSBullishHigh
01

Why it matters

FDA clearance makes Cosentyx the first and only anti-IL-17 biologic approved for PMR, supported by REPLENISH Phase 3 results after a 24-week steroid taper.

02

Market read

A first-in-class FDA approval for a defined PMR population is a direct, tradable catalyst for Novartis’ immunology franchise.

03

What to watch

The article does not quantify expected sales, pricing, or uptake; traders may need to watch formulary decisions and post-approval guidance from Novartis for confirmation.

Relevance 7/10Novelty 9/10Timing: FDA approval reported premarket Tuesday

Background

PMR is an inflammatory disorder affecting older adults, where standard care relies heavily on long-term corticosteroids despite relapse risk and steroid complications.

Company-level read

Ticker impact

$NVSBullishHigh confidence
Context

FDA approved Novartis’ Cosentyx 150 mg for polymyalgia rheumatica patients who inadequately respond to or cannot taper off corticosteroids.

Expected impact

Likely upward bias as markets price in incremental demand for Cosentyx in PMR and reduced reliance on long-term steroids.

Evidence & confidence

The article describes a first-in-class anti-IL-17 biologic approval for a defined PMR population, backed by Phase 3 REPLENISH remission data and FDA clearance.

Market effects

Reinforces anti-IL-17 biologics as viable steroid-sparing therapies in immune-mediated inflammatory disease, potentially sharpening competitive expectations in rheumatology.

US regulatory approval can shift sentiment toward large-cap pharma with late-stage immunology pipelines.

Global PMR treatment standards may evolve as FDA-cleared data are used by clinicians and payers beyond the US.

Counterpoint

Even with approval, real-world adoption may be slower due to payer restrictions, clinician inertia, and the need to demonstrate steroid-sparing benefits versus existing options.

Key entities

  • Novartis

    Sponsor of Cosentyx, which received FDA approval for PMR in steroid-inadequate or steroid-intolerant adults.

  • Cosentyx (secukinumab)

    Anti-IL-17 biologic approved at 150 mg for PMR with inadequate corticosteroid response or inability to taper.

  • FDA

    Approved the new indication based on REPLENISH Phase 3 data.

  • REPLENISH trial

    Phase 3 study showing higher sustained remission rates at week 52 after steroid taper.

Related articles

$NVSMed

FDA Approves Secukinumab as First Anti–IL-17 Biologic for PMR

The FDA approved a 150-mg dose of secukinumab (Cosentyx, Novartis) for polymyalgia rheumatica (PMR), making it the first anti-IL-17 biologic for this condition. The approval was based on the phase 3 REPLENISH trial, which showed higher remission rates with secukinumab plus a glucocorticoid taper compared to the taper alone. According to Novartis, this is the 11th US indication for secukinumab.

$NVSMed

Cosentyx Wins FDA Approval for Polymyalgia Rheumatica Patients Who Cannot Taper Steroids, Doubling Sustained Remission in Trial

Novartis' Cosentyx (secukinumab) 150 mg received FDA approval for polymyalgia rheumatica in patients who cannot taper steroids. The approval follows a trial where 40.5% of patients on Cosentyx achieved sustained remission at one year, compared to 20.5% on placebo. Cosentyx is the first IL-17 blocking biologic approved for this condition, according to Novartis.

$NVSMed

Novartis reports positive phase 3 data on ianalumab for Sjögren’s

Novartis reported positive long-term phase 3 data for ianalumab in Sjögren’s disease, showing improved disease activity and a favorable safety profile. The FDA granted Breakthrough Therapy Designation in January, with a decision expected this year. Ianalumab is also being investigated for other autoimmune diseases. Novartis aims to address the unmet need for disease-modifying treatments in Sjögren’s.

$NVSMed

FDA Clears Secukinumab for Use in Polymyalgia Rheumatica

The FDA approved Novartis' secukinumab (Cosentyx) for treating polymyalgia rheumatica (PMR) in adults unresponsive to corticosteroids. The approval follows positive phase 3 REPLENISH trial results, showing sustained remission rates of 41.2% and 40.6% for 300 mg and 150 mg doses, respectively, compared to 20.4% for placebo. Secukinumab is already approved for several other inflammatory conditions.

$NVSMed

FDA Approves Secukinumab as First IL-17 Biologic for Polymyalgia Rheumatica

The FDA approved Novartis' secukinumab (Cosentyx) 150 mg for polymyalgia rheumatica (PMR) in adults with inadequate corticosteroid response. The approval follows phase 3 trial results showing sustained remission in 40.5% of patients vs. 20.5% on placebo. Secukinumab is the first IL-17 biologic approved for PMR, offering a new treatment option with a steroid-sparing effect.